FDA Approves Two Medications for Idiopathic Pulmonary Fibrosis
Until Wednesday, people with idiopathic pulmonary fibrosis (IPF) had limited treatment options. Treatment options for this chronic lung condition expanded when the US Food and Drug Administration (FDA) approved two separate medications to treat IPF.